First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis

BACKGROUND: Infliximab (IFX) is one of the treatments of choice for corticosteroid-refractory and corticosteroid-dependent ulcerative colitis (UC). A high serum trough level of IFX (TL) is reported to be associated with sustained efficacy during maintenance treatment. As part of a phase 3 randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Taku, Suzuki, Yasuo, Motoya, Satoshi, Hirai, Fumihito, Ogata, Haruhiko, Ito, Hiroaki, Sato, Noriko, Ozaki, Kunihiko, Watanabe, Mamoru, Hibi, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2015
Materias:
Original Article—Alimentary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766223/
https://www.ncbi.nlm.nih.gov/pubmed/26162647
http://dx.doi.org/10.1007/s00535-015-1102-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766223/
https://www.ncbi.nlm.nih.gov/pubmed/26162647
http://dx.doi.org/10.1007/s00535-015-1102-z

Ejemplares similares